Introduction
There have recently been important advances in our understanding of asthma mechanisms and treatment. Asthma is now recognized as a disease of the airways which involves a special type of inflammation, characterized by the presence of activated mast cells, eosinophils and T-lymphocytes. There has been a growing recognition that chronic rather than acute inflammatory events are more relevant to understanding the underlying mechanisms in asthma and the role ofcytokines, as mediators of chronic inflammation, has been an area of very rapid development. At the same time the approach to asthma treatment has changed, with a much greater emphasis on the earlier and more widespread use of inhaled anti-inflammatory drugs, and particularly inhaled steroids. There has also been an increased understanding of the mechanisms of action of existing anti-asthma therapies, but at the same time questions have been raised about the safety of some treatments. This has prompted the search for novel anti-asthma therapies, based on our current understanding of pathophysiological mechanisms. The literature on asthma is vast and we do not intend to provide an exhaustive or comprehensive review, but have concentrated on some areas where there have been advances in knowledge which have clinical and therapeutic relevance.
Epidemiology
Asthma is one of the commonest diseases in industrialized countries and has a large economic impact in terms of health costs and loss of time from work. The total costs for asthma in the USA were recently estimated as $6.2 billion, representing 1% ofall US health care costs.' There have recently been several studies which indicate that the prevalence of asthma has increased over the last few years.2 A study in Finnish army conscripts has revealed a marked increase in the number of recruits with a diagnosis of asthma.3 In the UK there is evidence for similar trends. 4 Admission of children to hospital with asthma attacks has more than doubled over the last 10 years in the UK. 5 The reasons for this increase in morbidity are uncertain, since it is difficult to identify a single factor in the environment which has changed over the same time frame. There has been concern about air pollution, but little direct evidence to link specific changes in air quality to worsening of asthma.6 It is likely that an interaction between different air pollutants is important. A recent study investigated whether a common air pollutant, ozone, had any influence on allergen challenge in a group of mild asthmatic patients. A concentration of ozone as low as 0.12 parts per million, which itself had no effect on airway function, led to an increase in both the early and late response to inhaled allergen.7 Nitrogen dioxide (NO2) is a pollutant which is particularly associated with car exhaust fumes but there are few studies which have examined its airway effects or whether it interacts with other air pollutants or with allergen.
Allergen exposure is probably the most important factor in determining asthma severity. Exposure to allergen in early life is an important risk factor in the subsequent development of asthma. There is a striking association between the dust levels of Der p1 (the major allergen of house dust mite) at the time of birth and the prevalence of asthma at 11 years of age,8 although current levels of exposure may have been a confounding factor in this study. Increased allergen exposure has been implicated in the increase in asthma and the 'tight' houses, with poor ventilation and central heating increasingly found in temperate climates, may increase the house dust mite population and the concentration of indoor pollutants such as cigarette smoke.9
Another possible factor contributing to the increased morbidity and even mortality of asthma may be the use of anti-asthma medication, and in particular the excessive use of inhaled P-agonists. integrin adhesion molecules also referred to as CD49/CD29. Neutrophils do not show evidence of VLA-4, whereas eosinophils and basophils both expressed VLA-4. IL-4 selectively induces VCAM-1 expression49 and VLA-4 has been shown to increase adhesiveness in endothelial cells for eosinophils and basophils,47 but not neutrophils. The VLA-4 molecule can also function as an alternative receptor for fibronectin5" and eosinophils also express VLA-6 which binds laminin. Thus, the ability of eosinophils to remain localized within the extravascular inflammatory site may be increased in tissues expressing higher levels of laminin and/or fibronectin.
The role of adhesion molecules in asthma was strongly supported by evidence from Wegner and colleagues5' who identified the relationship between eosinophilic infiltration and airways responsiveness in the primate model of asthma. The administration of anti-ICAM-1 monoclonal antibody in vivo reduced eosinophil infiltration in airways hyperresponsiveness following antigen inhalation challenge. The type of response in the airways was dependent upon the model employed. When a subset of intrinsically hypereosinophilic animals were given a single inhaled allergen challenge, there was both an immediate and a delayed asthmatic response. The latter was associated with a neutrophil influx into the airways and an associated airways hyperresponsiveness which was inhibited by anti-ELAM-l but not anti-ICAM-l 52
The beta agonist debate Inhaled P2-adrenoceptor agonists are by far the most effective bronchodilators currently available and their use has increased dramatically in recent years throughout the world.
Mechanism ofaction
The molecular mechanism of their bronchodilator action has recently been elucidated; although several effects of P-agonists have been described, RECENT ADVANCES IN ASTHMA 945 the most important mechanism of action involves activation of a large conductance calciumactivated potassium channel (known as the maxi-K channel), which is blocked by the scorpion venom toxin charybdotoxin. Charybdotoxin blocks the bronchodilator action of P-agonists in both animal and human airways,53'54 and there is recent evidence that the ,82-receptor in airway smooth muscle cells is directly coupled via a stimulatory G-protein (Gj) to the maxi-K channel, without the involvement of the second messenger cyclic AMP.55 There has been considerable debate about the non-bronchodilator/anti-inflammatory effects of P-agonists. PAgonists are effective in inhibiting microvascular leakage and plasma exudation in the airways,56 '57 and inhibit mast cell mediator release. In this respect they could be considered as antiinflammatory agents, but they do not seem to have effects on the chronic inflammatory process and therefore do not have steroid-like actions. This is shown most directly by the lack of effect of treatment with a regular inhaled P-agonist on the inflammatory cell profile in bronchial biopsies taken from asthmatic patients, whereas inhaled steroids are very effective in suppressing the inflammatory response. 58 Similarly the new longacting inhaled P-agonist salmeterol has no effect on the profile or activation of inflammatory cells in biopsies of asthmatic patients. 59 Clinical evidence that this is so is provided by a study which compared regular inhaled P-agonist with regular inhaled steroids over a 2 year period in over 100 newly diagnosed patients.' There was a marked difference between the two groups with more frequent symptoms and use of rescue bronchodilators, greater diurnal variability and greater airway responsiveness in the group treated with P-agonists alone.
Questions about safety
Although P-agonists are highly effective as bronchodilators, questions have recently been raised about their long-term safety in asthma when used on a regular basis.6' Epidemiological studies in New Zealand suggested that there may be a link between the use of a particular P2-agonist fenoterol and the risk of asthma death. The original study was criticized because of the matching of controls but a further study which took this into account still showed an association.62 An epidemiological study in the Province of Saskatchewan in Canada examined the link between death and near death from asthma and the use of anti-asthma medication obtained from computerized records over a 7 year period.63 There was a significant association between asthma death and near death and the regular use of inhaled P-agonists, with a very steep dose-response relationship. The The effect of P-agonists on asthma morbidity may relate to the fact that P-agonists control asthma symptoms without controlling the underlying chronic inflammation so that patients may fail to take regular inhaled anti-inflammatory treatments. P-Agonists may paradoxically increase airway hyperresponsiveness in asthmatic patients, and there may be a rebound increase in responsiveness when P-agonists are stopped.61 Another hypothesis is that P-agonists inhibit the release of mediators such as heparin from mast cells, since heparin may have anti-inflammatory properties,73 although the amount of heparin which is released from mast cells is likely to be very low. Other theories suggest that increased viscous mucus secretion may be a factor, whereas others suggest that the bronchodilator response to P-agonists allows more allergen to be inhaled into the lower airways where a chronic inflammatory response is initiated. 74 In studies in guinea pigs the nonbronchodilating (+) enantiomer of P-agonists may increase airway responsiveness, suggesting that the normal racemic ( ± ) P-agonists such as salbutamol, terbutaline and fenoterol may be deleterious,75 although whether these considerations are clinically relevant remains to be determined. The clinical implication of these studies is that short-acting inhaled P-agonists should only be used on demand for symptom control and should never be used on a regular basis. In 
Steroid-resistant asthma
Corticosteroid resistance in some patients with asthma has been recognized for many years, but the mechanisms are far from clear. The importance of this phenomenon is that it may provide important clues to understanding the mechanism of action of corticosteroids in asthma. One action of steroids is to increase the synthesis of lipocortin-1 which has some anti-inflammatory effects. Two studies have demonstrated that antibodies to lipocortin-1 are not elevated in steroid-resistant asthmatic.92 '93 There is evidence that T-lymphocytes show reduced responsiveness to steroids in vitro which is correlated with reduced in vivo responsiveness. 94 This does not appear to be due to a defect in steroid binding to the glucocorticoid receptor,95 but a defect in binding ofthe activated steroid receptor to steroid responsive elements on target genes has not been excluded. The defect in steroid responsiveness is also seen in monocytes from these patients. Side effects include headache, flushing and postural hypotension, due to vasodilatation. It will therefore be necessary to develop these drugs for inhalational use in order to avoid these effects, although it may be possible to develop K+ channel openers which are more selective for airway than vascular smooth muscle, in view of the diversity of K+ channels. One such airway selective K+ channel opener (BRL 55834) has already been described.'28 The future success of these compounds in asthma will probably depend on whether they have any additional effects not shared with ,B-agonists. K+ Inhaled frusemide protects against 'indirect' bronchoconstrictor challenges, such as exercise, fog, allergen, sodium metabisulphite and adenosine, but has no effect against direct bronchoconstrictor challenges such as histamine, methacholine and PGF2t,.'" These effects mimic those of sodium cromoglycate but, in addition, inhaled frusemide inhibits certain types of induced cough."'' The mechanism of action of frusemide in asthma is not certain, but it is ineffective systemically, suggesting that it is acting at the airway surface. Frusemide works as a diuretic by inhibiting the Na+/K+/Clcotransporter in renal tubular cells, but the more potent inhibitor bumetanide is ineffective in the same challenges.'52 Some effects of frusemide are mediated by the release of PGE2, but cyclooxygenase inhibition does not abolish the antiasthma effect. The most likely possibility is that frusemide blocks a certain type of Cl-channel which is necessary for the activation of inflammatory cells and sensory nerves.
Immunomodulators T-lymphocytes may play a critical role in initiating and maintaining the inflammatory process in asthma via the release of cytokines. Methotrexate has a steroid-sparing effect in asthma, probably acting as a non-specific immunosuppressive or anti-inflammatory agent.'53" 54 The side effects of methotrexate (particularly nausea and blood dyscrasias) preclude its use in all but the most severe asthmatic patients who have problems with oral steroids.
More specific immunomodulators, such as cyclosporin A, which have an inhibitory effect on T-lymphocyte function, might be more useful in controlling asthma, and there is some evidence that low-dose cyclosporin A improves lung function in steroid-dependent asthmatics.32"55 The nephrotoxicity of cyclosporin A would limit its widespread use but derivatives with less nephrotoxicity are now being developed and the possibility ofusing inhaled cyclosporin is being explored. Other immunomodulators such as FK506 and rapamycin appear to be more potent and less toxic. '56 In the future it may be possible to develop more specific inhibitory drugs. There is particular interest in the development of an inhibitor of IL-5 synthesis or receptor antagonist, since blocking IL-5 with a monoclonal antibody appears to inhibit eosinophil infiltration into the airways completely after allergen exposure.'57 An endogenous IL-1 antagonist (IL-Ira) has recently been cloned, which competes with IL-I for binding to IL-I receptors. '58 This antagonist has an inhibitory effect on the hyperresponsiveness and leukocyte infiltration following allergen challenge in guinea pigs, '9 suggesting that it may have therapeutic potential in asthma. 
